Author: Jean-Francois Korobelnik (France)
Co-authors: Michael Larsen, Nicole Eter, Clare Bailey, Sebastian Wolf, Kay Rittenhouse, Helmut Allmeier
Purpose
The aim of the CENTERA study was to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) administered using a proactive, individualized treat-and-extend (T&E) dosing regimen in patients with macular edema secondary to central retinal vein occlusion (CRVO). The primary results, including safety, of the CENTERA study have been previously published. This post hoc analysis of the CENTERA study assessed baseline (BL) characteristics, treatment intervals, as well as functional (best-corrected visual acuity [BCVA]) and anatomic (central retinal thickness [CRT]) outcomes of patients who achieved treatment success based on study criteria similar to LEAVO (BCVA of ≥83 letters achieved at any point during treatment).
Setting/Venue
CENTERA (NCT02800642) was a 76-week, multicenter, open-label, single-arm, Phase 4 study performed at 42 sites in Canada, Europe, and Australia. Treatment-naïve patients aged ≥18 years with center-involved macular edema secondary to CRVO, and BCVA of 73–24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the study eye were enrolled.
Methods
Patients with macular edema secondary to CRVO received 2 mg IVT-AFL injections at BL and every 4 weeks until disease stability criteria were met, or until Week 20, whichever occurred first (initiation phase). The treatment interval was adjusted in 2-week increments based on functional and anatomic outcomes, as assessed by the investigator (T&E phase). Monitoring occurred at each injection and mandatory visit (Weeks 24, 52, and 76). Co-primary endpoints were the proportion of patients who gained ≥15 letters from BL to Week 76 and the proportion of patients with a mean treatment interval of ≥8 weeks from the last initiation phase visit to Week 76. Safety was assessed throughout the study. A post hoc sensitivity analysis of the second co-primary endpoint was conducted based on study criteria similar to LEAVO for treatment success. In this sensitivity analysis, patients who achieved ≥83 letters at any point were considered treatment successes and, therefore, to have met the second co-primary endpoint of achieving a mean treatment interval of ≥8 weeks. The proportion of patients who maintained robust vision gains (achieved ≥83 letters and did not lose >5 letters thereafter) was also assessed.
Results
The full analysis set (FAS) comprised 160 patients (n=74 [≥83 letter group; mean±SD BL BCVA 61.2±12.3] and n=86 [<83 letter group; BL BCVA 44.0±16.2]). Overall, 65.6% (n=105; 95%CI, 57.7–72.9, p<0.0001 [test against 40% threshold]) of patients in the FAS gained ≥15 letters from BL to Week 76. During the T&E phase, 45.0% (n=72; 95%CI, 37.1–53.1, p=0.8822 [threshold of 50%]) of patients in the FAS achieved a mean treatment interval of ≥8 weeks. In the sensitivity analysis of the second co-primary endpoint, where patients who achieved ≥83 letters at any point were considered treatment successes and therefore to have met this endpoint, 66.3% (n=106; 95%CI, 58.4–73.5, p<0.0001 [50% threshold]) of patients achieved a mean treatment interval ≥8 weeks or treatment success during the T&E phase. Of the patients who achieved ≥83 letters at any point, 54.1% (n=40) maintained vision. Mean change in BCVA from BL to Week 76 was +23.9±13.6 (≥83 letter group) letters and +17.3±23.1 (<83 letter group) letters. At BL, mean CRT was 695.6±226.4 (≥83 letter group) µm and 816.6±249.9 (<83 letter group) µm. Mean change in CRT from BL to Week 76 was −419.8±235.0 (≥83 letter group) µm and −563.4±249.3 (<83 letter group) µm.
Conlusions
In the CENTERA study, clinically meaningful and significant improvements in functional and anatomic outcomes were achieved with IVT-AFL administered using a proactive, individualized T&E regimen in patients with macular edema secondary to CRVO. An appreciable proportion of patients in CENTERA achieved high BCVA (≥83 letters) following IVT-AFL T&E treatment. This sensitivity analysis indicated that, if similar criteria to LEAVO for treatment success had been used, most patients could have achieved a mean treatment interval of ≥8 weeks or treatment success during the T&E phase. Of the patients who achieved ≥83 letters at any point during the study, over half not only achieved, but also remained at ≥83 letters. In addition, patients who achieved ≥83 letters at any point during the study had higher BCVA and lower CRT at BL, compared with those who did not achieve ≥83 letters. In both groups, patients demonstrated BCVA gains and improved CRT, demonstrating that IVT-AFL administered using a proactive, individualized T&E regimen optimizes visual acuity gains and normalizes CRT irrespective of BL status.
Financial Disclosure
Jean-François Korobelnik: Consultant for Allergan, Bayer, Janssen, Kanghong, Novartis, Novonordisk, Roche, Thea, Zeiss
Michael Larsen: Study investigator and consultant for (and the Rigshospitalet has received compensation for clinical trials from) AbbVie, Acucela, Alcon, Allergan, Bayer, GlaxoSmithKline, Novartis, and Novo Nordisk
Nicole Eter: Consultant for Alimera, Allergan, Bayer, Novartis, Roche
Clare Bailey: Attendance at advisory boards/lecture fees for Alimera Sciences, Bayer, Novartis, and Roche
Sebastian Wolf: Consultant for Allergan, Bayer, Heidelberg Engineering, Novartis, Optos Inc, Roche, Zeiss; Grant support from Heidelberg Engineering
Kay Rittenhouse: Employee of Bayer Consumer Care AG, Basel, Switzerland
Helmut Allmeier: Employee of Bayer Consumer Care AG, Basel, Switzerland
Tobias Machewitz: Employee of Bayer AG, Berlin, Germany
Varun Chaudhary: Grants from Allergan Inc, Bayer Healthcare, and Novartis Pharma AG; Scientific advisor for Alcon Laboratories, Bayer Healthcare, and Novartis Pharma AG; Advisory board member for Roche
Funding: The CENTERA study was funded by Bayer AG, Germany. Medical writing support was provided by ApotheCom, and funded by Bayer Consumer Care AG, Pharmaceuticals, Switzerland.
Comments
Important add below co-authors: 7. Tobias Machewitz: Bayer AG, Berlin, Germany 8. Varun Chaudhary: Hamilton Regional Eye Institute, St. Joseph’s Healthcare Hamilton, McMaster University, Hamilton, ON, Canada